DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Human Chorionic Gonadotropin Supplementation Prior to In-vitro Fertilization Treatment in Poor Responders

Information source: Hadassah Medical Organization
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Infertility

Intervention: Ovitrelle (Drug)

Phase: N/A

Status: Not yet recruiting

Sponsored by: Hadassah Medical Organization

Official(s) and/or principal investigator(s):
Mushira Aboo Dia, MD, Principal Investigator, Affiliation: Hadassah Medical Center

Overall contact:
Mushira Aboo Dia, , MD, Email: mushiraa@gmail.com


In an era of delayed fertility plans, there is increasing need for fertility treatment in older women with poor response. Human chorionic gonadotropin (hCG) supplementation prior to treatment, as a thecal stimulant, may improve folliculogenesis and ovarian response.

Clinical Details

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: number of oocytes retrieved


Minimum age: 40 Years. Maximum age: 45 Years. Gender(s): Female.


Inclusion Criteria:

- women >39 years on IVF treatment

Exclusion Criteria:

- polycystic ovary syndrome

- Any allergy to injection of human chorionic gonadotropin before

Locations and Contacts

Mushira Aboo Dia, , MD, Email: mushiraa@gmail.com

Hadassah Medical Center, Jerusalem, Israel; Not yet recruiting
Arik Tzukert, DMD, Phone: 0097226776095, Email: arik@hadassah.org.il
Mushira Aboo Dia, MD, Phone: 0097226776425, Email: mushiraa@gmail.com
Additional Information

Starting date: April 2011
Last updated: March 1, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017